Phase I Decitabine DNA-methyltransferase inhibitor trial in surgically resectable HPV-negative head and neck cancer

This Phase I trial at Mayo Clinic evaluates the safety, dose tolerance, and potential efficacy of decitabine when given before standard-of-care surgery followed by radiation and chemotherapy. It enrolls patients with surgically resectable, HPV-negative head and neck squamous cell carcinoma, investigating if decitabine’s DNA methyltransferase inhibition can enhance treatment effectiveness.